

<Press Release>
May 19, 2022

Chordia Therapeutics Concludes Basic Agreement on Business Tie up
with MEDIPAL HOLDINGS CORPORATION

Kanagawa, Japan, May 19, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it signed a basic agreement on collaboration with MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) on May 13, 2022.

Based on the basic agreement of this collaboration, the two companies will proceed with specific discussions toward the alliance. Chordia believes that MEDIPAL’s distribution network in Japan and various sales promotion functions such as RD-MR^{*1} and Clinical Cloud by MEDIPAL^{*2} will greatly contribute to Chordia’s market penetration when marketing its drugs currently under development in Japan. Chordia expects that this collaboration will contribute to delivering new treatment methods to patients.

- *1 RD-MR (Rare Disease MRs): A designation within MEDIPAL given to MSs (Marketing Specialists of pharmaceutical wholesalers) and pharmacists who have passed the MR certification exam and are engaged in information provision activities focused on rare diseases.
- *2 Clinical Cloud by MEDIPAL: An information provision platform for healthcare professionals provided by MEDIPAL.

About MEDIPAL HOLDINGS CORPORATION

Established: May 1923
Business Description: As a holding company, MEDIPAL HOLDINGS controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.
Location: 2-7-15, Yaesu, Chuo-ku, Tokyo 104-8461 Japan
Representative: Shuichi Watanabe, Representative Director, President and CEO
Website: <https://www.medipal.co.jp/english/>

About Chordia Therapeutics

Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chorditherapeutics.com



the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

The CLK inhibitor CTX-712, which is currently under development as the lead program, is currently undergoing Phase I clinical trials in Japan for patients with advanced, relapsed, or refractory malignancies. CTX-712 targets vulnerabilities resulting from RNA deregulation, which has been identified as a new hallmark of cancer, and is expected to be an effective therapeutic agent.

In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2 chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact Kentaro Kume, IR: info@chorditherapeutics.com